Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BUTORPHANOL vs CABOZANTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

BUTORPHANOL vs CABOZANTINIB: Safety Overview

Metric BUTORPHANOL CABOZANTINIB
Total FAERS Reports 462 3,831
Deaths Reported 10 767
Death Rate 2.2% 20.0%
Hospitalizations 24 2,771
Average Patient Age 53.9 yrs 62.2 yrs
% Female Patients 79.2% 27.5%
FDA Approval Date Approved Prior to Jan 1, 1982 N/A
Manufacturer Hikma Pharmaceuticals USA Inc. N/A
Route NASAL N/A
Marketing Status Discontinued None